Profile: Eurand N.V. (EURX.O)

Eurand N.V. (Eurand), formerly known as Eurand B.V., incorporated in 1984, is a specialty pharmaceutical company. The Company develops, manufactures and commercializes pharmaceutical and biopharmaceutical products based on its drug formulation technologies. Through its collaboration arrangements, Eurand has applied its technologies to drug products in a range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory. It develops and commercializes its own portfolio of products to address cystic fibrosis and gastrointestinal disorders. Eurand is an established business with manufacturing and research facilities in the United States, Italy and France. It manufactures and supplies over 40 different products for sale in pharmaceutical markets.

EUR-1008 or Zentase

The Company’s product candidate, EUR-1008, is a porcine-derived proprietary enzyme replacement product (PEP) being developed for the treatment of exocrine pancreatic insufficiency (EPI). EPI is a deficiency of digestive enzymes produced and secreted by the pancreas. EUR-1008 is a formulation of a porcine-derived PEP, which contains eight digestive enzymes, as well as a number of cofactors and coenzymes that are necessary for the proper digestion of food. The enzyme profile of EUR-1008 closely mimics that of normal human pancreatic secretions. It received an approvable letter for EUR-1008 from the FDA in June 2008.

SourceCF Product Portfolio

Eurand provides products and services to the Cystic Fibrosis (CF) community (patients, physicians and care givers). The Company’s subsidiary, Eurand Pharmaceuticals, Inc., markets a portfolio of cystic fibrosis specialty products (the SourceCF product portfolio) through its subsidiary, SourceCF. The SourceCF product portfolio includes a portfolio of vitamins, designed specifically for CF patients, and the eFlow electronic nebulizer, a device frequently required by CF patients.

Amrix

Amrix, developed with ECR Pharmaceuticals using Diffucaps technology, is a once-a-day (OAD) sustained release formulation of cyclobenzaprine hydrochloride, for use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions marketed under the tradename Amrix. Amrix is FDA approved OAD skeletal muscle relaxant in the United States.

EUR-1037 or Unisom Sleepmelts

EUR-1037 is an orally disintegrating tablet formulation of Diphenhydramine citrate, that the Company developed using its AdvaTab and Microcaps technologies. The product is sold as an over-the-counter (OTC) product by Chattem Inc. in the United States under the brand name Unisom Sleepmelts. The product was launched in April 2008.

EUR-1048

EUR-1048 is a taste-masked, orally disintegrating tablet formulation of an undisclosed active, that the Company developed using AdvaTab and Microcaps technologies. GSK is responsible for certain regulatory filings and is granted a license to sell the product in the United States. The Company retains certain rights to the product outside the United States. In addition to development payments, milestone payments and manufacturing fees, the Company is entitled to receive royalties based on a percentage of GSK’s net sales of the product.

The Company competes with Par Pharmaceuticals Companies, Inc., Mylan Pharmaceuticals, Inc., Axcan Pharma, Johnson & Johnson, Solvay Pharmaceuticals, KV Pharmaceuticals, IMPAX Laboratories, Altus Pharmaceuticals, Biovitrum, Zentase, Biovail, Elan, Skye Pharma, Cima and KV Pharmaceuticals.